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Letter to the Editor
Letters to the Editor will be published, if suitable, as space permits. They should not exceed 1000 words
(typed double-spaced) in length and may be subject to editing or abridgment.
Blood Pressure Control: A Facelift
for Macrophages?
To the Editor:
Machnik et al1,2 recently demonstrated a new physiological
role for macrophages in regulating salt-dependent volume and
blood pressure by a vascular endothelial growth factor C–depen-
dent buffering mechanism. In line with this work, they now
extend their work demonstrating that the mononuclear phagocyte
system depletion induces salt-sensitive hypertension in rats.1,2
These findings promote a new view on a protective role for
macrophages in hypertension. Although cardiovascular inflam-
mation has been widely evidenced to have detrimental effect on
blood pressure and target organ damage,3 the common view
needs to be differentiated, because macrophages in the lymphatic
compartment seem to be protective with respect to salt-sensitive
blood pressure regulation.
An important feature in this scenario is obviously the sodium
homeostasis. The influence of sodium on blood pressure is not
only restricted to models used by Machnik et al1,2 but also
influences other more general models of hypertension, such as
the spontaneously hypertensive rat (SHR).4 Therefore, it is
relevant to know whether the observed blood pressure effects
after macrophage depletion in salt-sensitive models of hyperten-
sion are reproducible in models where macrophage action has
been rather associated with deleterious effects.
In a preliminary study we used the same source and strategy to
deplete macrophages in adult SHRs, as performed by Machnik et
al.1 Age-matched liposome-treated SHRs and normotensive
Wistar-Kyoto rats were used as controls (n5 each group), and
macrophage depletion was confirmed by fluorescence-activated
cell sorter analysis. In contrast to Machnik et al,1 we, further-
more, used radiotelemetry during the whole treatment period as
the gold standard technique for blood pressure control in all of
the groups. Despite appropriate macrophage depletion in clodr-
onate-liposome–treated SHRs, we did not observe a blood
pressure difference during the 2 weeks of intervention between
clodronate-liposome– or control-liposome–treated SHRs (mean
arterial pressure: 137.54.4 versus 139.61.8 mm Hg). Wistar-
Kyoto rats receiving control liposomes had a blood pressure of
103.13.9 mm Hg. Therefore, our preliminary data do not
demonstrate that macrophage depletion has a detrimental blood
pressure influence in a standard model of hypertension, which
has also been demonstrated to be at least partially sodium
dependent. Furthermore, protective cardiovascular effects of
macrophage depletion need to be further investigated, because
already several years ago colleagues of Machnik demonstrated
the blood pressure–lowering effect of immunosuppressive treat-
ment with mycophenolate mofetil in another hypertensive rat
strain.3 Moreover, the group of Schiffrin5 demonstrated that
osteopetrotic mice that miss macrophage colony-stimulating
factor exhibit no blood pressure increase and reduced vascular
inflammation during desoxycorticosterone acetate-salt
intervention.
In our view, it will be highly interesting to differentiate the
protective and deleterious (probably compartment-dependent)
effects of macrophages on blood pressure and cardiovascular
damage in the various types of hypertensive models. In this
context, the work of Machnik et al1 offers the basic understand-
ing of protective macrophage effects that needs to be cautiously
put in context with our common view of cardiovascular inflam-
matory processes.
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